Step-Ups in Convergence Plays
This article was originally published in Start Up
Executive Summary
The rationale for drug-device convergence companies-combining the device sector's speed to market and relative lack of clinical risk with the biopharma sector's margins-may be gaining some traction as of late. Half of the eight device IPOs to close so far this year, in fact, are arguably convergence plays.